Insulet Corporation (NASDAQ:PODD) Stock Has Consensus Price Target of $195.40 According to Analysts

Shares of Insulet Corporation (NASDAQ:PODD) have earned a consensus recommendation of “Hold” from the twenty-six ratings firms that are presently covering the stock, Marketbeat reports. Two analysts have rated the stock with a sell recommendation, eleven have assigned a hold recommendation and thirteen have assigned a buy recommendation to the company. The average 1 year target price among brokerages that have updated their coverage on the stock in the last year is $195.40.

Several research analysts have weighed in on the stock. JPMorgan Chase & Co. restated a “neutral” rating and set a $152.00 target price (down from $275.00) on shares of Insulet in a research report on Thursday, August 6th. TD Cowen decreased their price target on Insulet from $294.00 to $144.00 and set a “hold” rating on the stock in a research note on Thursday, August 6th. Sanford C. Bernstein lowered their price target on Insulet from $200.00 to $175.00 and set an “outperform” rating on the stock in a report on Thursday, August 6th. Robert W. Baird set a $175.00 price target on Insulet in a report on Thursday, August 6th. Finally, Citigroup raised their price objective on Insulet from $165.00 to $172.00 and gave the company a “neutral” rating in a research note on Wednesday, July 8th.

Insulet Price Performance

Shares of NASDAQ PODD opened at $131.69 on Wednesday. The company has a debt-to-equity ratio of 0.65, a quick ratio of 1.83 and a current ratio of 2.48. Insulet has a one year low of $126.40 and a one year high of $354.88. The firm has a market capitalization of $9.13 billion, a P/E ratio of 24.61, a PEG ratio of 1.03 and a beta of 1.11. The company’s fifty day moving average is $144.92 and its two-hundred day moving average is $162.91.

Insulet (NASDAQ:PODD) last announced its quarterly earnings results on Wednesday, August 5th. The medical instruments supplier reported $1.66 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.47 by $0.19. Insulet had a net margin of 12.29% and a return on equity of 29.29%. The business had revenue of $801.70 million during the quarter, compared to the consensus estimate of $787.39 million. During the same quarter last year, the firm posted $1.17 EPS. The business’s revenue was up 23.5% compared to the same quarter last year. Insulet has set its FY 2026 guidance at 6.460- EPS. Analysts forecast that Insulet will post 6.51 EPS for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the company. State of Wyoming lifted its position in Insulet by 34.6% during the first quarter. State of Wyoming now owns 284 shares of the medical instruments supplier’s stock worth $60,000 after buying an additional 73 shares during the period. Optas LLC boosted its stake in Insulet by 8.8% in the 1st quarter. Optas LLC now owns 1,059 shares of the medical instruments supplier’s stock worth $222,000 after buying an additional 86 shares during the last quarter. American Trust grew its holdings in Insulet by 8.6% in the 1st quarter. American Trust now owns 1,180 shares of the medical instruments supplier’s stock valued at $248,000 after buying an additional 93 shares during the period. Basecamp Wealth Advisors LLC grew its holdings in Insulet by 48.3% in the 1st quarter. Basecamp Wealth Advisors LLC now owns 313 shares of the medical instruments supplier’s stock valued at $66,000 after buying an additional 102 shares during the period. Finally, MV Capital Management Inc. acquired a new position in shares of Insulet during the 4th quarter valued at about $29,000.

Insulet Company Profile

Insulet Corporation is a medical device company that develops, manufactures and markets wearable insulin delivery systems for people with diabetes. The company is best known for its Omnipod platform, which is designed to provide insulin delivery without the tubing traditionally associated with conventional insulin pumps.

Insulet’s product portfolio includes the Omnipod 5 Automated Insulin Delivery System, a tubeless, wearable system that integrates with continuous glucose monitoring technology to automate insulin delivery, as well as the Omnipod DASH system.